Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 3, 2012, Pages 207-212

  Cervera, Eduardo ^a   Candelaria, Myrna ^a   López Navarro, Omar ^a   Labardini, Juan ^a   Gonzalez Fierro, Aurora ^a   Taja Chayeb, Lucia ^a   Cortes, Jorge ^b   Gordillo Bastidas, Daniela ^a   Dueñas González, Alfonso ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myeloid leukemia; Epigenetic therapy; Imatinib resistance

Indexed keywords

ANTINEOPLASTIC AGENT; HYDRALAZINE PLUS VALPROATE MAGNESIUM; IMATINIB; TRANSKRIP; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; FEMALE; HUMAN; MALE; NAUSEA; NEUROTOXICITY; PRURITUS; RASH; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR;

ADULT; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDRALAZINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84861087737     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.01.005     Document Type: Article

References (46)

1. M.W. Deininger, J.M. Goldman, J.V. Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
2. S.G. O'Brien, F. Guilhot, R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004 (Pubitemid 36302244)
3. B.J. Druker, F. Guilhot, S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417 (Pubitemid 44903745)
4. S.G. O'Brien, F. Guilhot, J.M. Goodman International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) Blood 112 2008 76 (abstract 186)
5. H.M. Kantarjian, M. Talpaz, S.G. O'Brien Survival benefit with imatinib mesylate versus interferon-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia Blood 108 2006 1835 1840 (Pubitemid 44394991)
6. J. Cortes, R. Silver, H. Kantarjian Chronic myeloid leukemia W. Hong, R.C. Bast Jr W.N. Hait, Cancer Medicine 8th ed. 2010 People's Medical Publishing House Shelton, CT 1582 1590
7. H. Kantarjian, F. Giles, L. Wunderle Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2006 2542 2551 (Pubitemid 43882350)
8. H.M. Kantarjian, F. Giles, N. Gattermann Nilotinib (formerly AMN107), a highly selective bcr-abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 2007 3540 3546 (Pubitemid 350159618)
9. A. Hochhaus, H.M. Kantarjian, M. Baccarani Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2007 2303 2309 (Pubitemid 46425867)
10. H. Kantarjian, N.P. Shah, A. Hochhaus Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
11. G. Saglio, D.W. Kim, S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
12. H. Kantarjian, J. Cortes Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy J Clin Oncol 29 2011 1512 1516
13. G. Marcucci, D. Perrotti, M.A. Caligiuri Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance Commentary re: AN Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations Clin Cancer Res 9 2003 1333 1337
14. C. Tang, L. Schafranek, D.B. Watkins Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways Leuk Lymphoma 52 2011 2139 2147
15. F. Lee, A. Fandi, M. Voi Overcoming kinase resistance in chronic myeloid leukemia Int J Biochem Cell Biol 40 2008 334 343 (Pubitemid 351241231)
16. J. Jelinek, V. Gharibyan, M.R.H. Estecio Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia PLoS ONE 6 2011 e22110
17. S.M. Lee, J.H. Bae, M.J. Kim Bcr-Abl independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors J Pharmacol Exp Ther 322 2007 1084 1092
18. R. Nimmanapalli, L. Fuino, P. Bali Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells Cancer Res 63 2003 5126 5135 (Pubitemid 37022654)
19. R. Nimmanapalli, L. Fuino, C. Stobaugh Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib induced apoptosis of Bcr-Abl-positive human acute leukemia cells Blood 101 2003 3236 3239 (Pubitemid 36858020)
20. J.P. Issa, V. Gharibyan, J. Cortes Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate J Clin Oncol 23 2005 3948 3956 (Pubitemid 46218698)
21. C. Arce, B. Segura-Pacheco, E. Perez-Cardenas Hydralazine target: from blood vessels to the epigenome J Translat Med 4 2006 10
22. N. Singh, A. Dueñas-González, F. Lyko Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase ChemMedChem 1 2009 792 799 4
23. A. Duenas-Gonzalez, M. Candelaria, C. Perez-Plascencia Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors Cancer Treat Rev 34 2008 206 222
24. C. Arce, C. Pérez-Plasencia, A. González-Fierro A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer PLoS ONE 1 2006 e98
25. M. Candelaria, D. Gallardo-Rincón, C. Arce A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann Oncol 18 2007 1529 1538 (Pubitemid 47365487)
26. M. Candelaria, A. Herrera, J. Labardini Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome Preliminary results of a phase-II trial Ann Hematol 90 2011 379 387
27. M. Candelaria, L. Cetina, E. Pérez-Cárdenas Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer Eur J Gynaecol Oncol 31 2010 386 391
28. J. Coronel, L. Cetina, I. Pacheco A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer Preliminary results Med Oncol 28 suppl 4 2011 1507 1513
29. A. Dueñas-Gonzalez, M.T. Vega, D. Martinez-Baños Response to hydralazine-valproate in a patient with mycosis fungoides Case report Med Case Report Med 2010 2010 657579
30. J. Hasford, P. Pfirrmann, R. Hehlmann A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group J Natl Cancer Inst 90 1998 850 858 (Pubitemid 28280552)
31. J.E. Sokal, E.B. Cox, M. Baccarani Prognostic discrimination in 'good-risk' chronic granulocytic leukemia Blood 63 1984 789 799 (Pubitemid 14141296)
32. R. Hehlmann, A. Hochhaus, M. Baccarani European LeukemiaNet Chronic myeloid leukaemia Lancet 370 2007 342 350 (Pubitemid 47094995)
33. J.W. Vardiman, J. Thiele, D.A. Arber The 2008 revision of the world Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important change Blood 114 2009 937 951
34. A. Gonzalez-Fierro, D. Vasquez-Bahena, L. Taja-Chayeb Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype Int J Clin Pharmacol Ther 49 2011 519 524
35. E. San José-Eneriz, X. Agirre, A. Jiménez-Velasco Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia Eur J Cancer 45 2009 1877 1889
36. R.J. Li, G.S. Zhang, Y.H. Chen Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance Ann Oncol 21 2010 1506 1514
37. B. Brodská, P. Otevoelová, A. Holoubek Decitabine-induced apoptosis is derived by puma and noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA Mol Cell Biochem 350 2011 71 80
38. W. Fiskus, M. Pranpat, M. Balasis Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells Clin Cancer Res 12 2006 5869 5878 (Pubitemid 44629620)
39. E. Georgiou, S. Kouidou Epigenetically-targeted therapies for the treatment of hematological malignancies Curr Med Chem 18 2011 1757 1764
40. Y. Oki, H.M. Kantarjian, V. Gharibyan Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia Cancer 109 2007 899 906 (Pubitemid 46333532)
41. S. Pursche, E. Schleyer, M. von Bonin Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients Curr Clin Pharmacologist 3 2008 198 203
42. E. De la Cruz-Hernández, C. Perez-Plasencia, E. Pérez-Cardenas Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma Oncol Rep 25 2011 399 407 [PubMed]
43. F. Buchi, R. Pastorelli, G. Ferrari Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid Leuk Res 35 2011 921 931
44. S. Roychowdhury, M. Talpaz Managing resistance in chronic myeloid leukemia Blood Rev 25 2011 279 290
45. J. Cortes-Franco, D. Raghunadharao, P. Parikh Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study Blood 114 2009 861 (abstract)
46. F.J. Giles, E.J. Feldman, G.J. Roboz Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase Leuk Res 27 2003 1091 1096 (Pubitemid 36960028)